The 483

Tag

Novo Nordisk

14 stories

FDA

FDA Cleared Lilly Foundayo in $9.3B Obesity Race

FDA Cleared Lilly Foundayo in $9.3B Obesity Race
FDA

Novo Targets FDA Filing for Etavopivat After 27% VOC Reduction

Novo Targets FDA Filing for Etavopivat After 27% VOC Reduction
Deals

UCB Paid $1.15B for Neurona's Single-Dose Epilepsy Cell Therapy

UCB Paid $1.15B for Neurona's Single-Dose Epilepsy Cell Therapy
Deals

Raised $625M at $16 a Share, Kailera Tops Moderna's 2018 IPO Record

Raised $625M at $16 a Share, Kailera Tops Moderna's 2018 IPO Record
Deals

Kailera Prices $625M IPO, Largest Biotech Since Moderna

Kailera Prices $625M IPO, Largest Biotech Since Moderna
Deals

Priced at $16, Kailera Raises $625M in Largest Biotech IPO Since 2018

Priced at $16, Kailera Raises $625M in Largest Biotech IPO Since 2018
FDA

FDA Cleared Foundayo With 3 Postmarketing Safety Study Requirements

FDA Cleared Foundayo With 3 Postmarketing Safety Study Requirements
FDA

FDA Cleared Foundayo; Lilly Pre-Stocked $1.5B Before Approval

FDA Cleared Foundayo; Lilly Pre-Stocked $1.5B Before Approval
Deals

Novo Loses GLP-1 Pioneer Lotte Bjerre Knudsen to Retirement

Novo Loses GLP-1 Pioneer Lotte Bjerre Knudsen to Retirement
FDA

Lilly Foundayo Clears FDA; Novo's Oral Holds 5-Point Lead

Lilly Foundayo Clears FDA; Novo's Oral Holds 5-Point Lead
FDA

Novo Nordisk's 7.2 mg Wegovy Hits US Shelves at Triple the Standard Dose

Novo Nordisk's 7.2 mg Wegovy Hits US Shelves at Triple the Standard Dose
Deals

Anthropic Pays $400M for a 10-Person Ghost Company

Anthropic Pays $400M for a 10-Person Ghost Company
FDA

Novo Fires Back at Lilly's Foundayo With Competing Efficacy Data

Novo Fires Back at Lilly's Foundayo With Competing Efficacy Data
FDA

FDA Clears 7.2mg Wegovy HD for Novo Nordisk in 54-Day Sprint